Sources: Iambic: initial public offering pricing; City Therapeutics: upsized IPO pricing; SEC Investor Bulletin: Investing in an IPO

Base gross proceeds at the announced prices

US$ millions, rounded; pricing announcements October 14–15

0100200150Iambic200City Therapeutics
Before expenses; excludes unexercised additional-share options. Share count × offer price, not market value or investor return. [1][2]

Sources: [1] Iambic: initial public offering pricing · October 14, 2026; closing expected October 16; [2] City Therapeutics: upsized IPO pricing · October 15, 2026; closing expected October 19

This analysis examines the implications of the week’s verified reporting, the assumptions behind the financial measures and the developments to monitor next.

ORIGINAL ANALYSIS · MEMBER ACCESS

Go beyond the headline.

Premium articles cost $2 per article. Read this analysis with a one-time purchase, or explore every premium web article with Digital.

Library Pass includes every article and newspaper PDF for $299/year. Compare access →

A member account is required before payment. Already purchased? Sign in.